You are here

Spark Therapeutics

Why Roche's Acquisition Of Spark May Be Complete By Year's End

Why Roche's Acquisition Of Spark May Be Complete By Year's End

Investors Business Daily

Spark Therapeutics

Flag link:

With biosimilar threat under control (for now), Roche savors demand for its new drugs

With biosimilar threat under control (for now), Roche savors demand for its new drugs

Endpoints

Spark Therapeutics

Flag link:

Roche sets new deadline for Spark acquisition as divestiture speculation brews

Roche sets new deadline for Spark acquisition as divestiture speculation brews

Endpoints

Spark Therapeutics

Flag link:

Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already

Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already

Fierce Pharma

Spark Therapeutics

Flag link:

UK cost watchdog recommends Novartis' blindness therapy Luxturna

UK cost watchdog recommends Novartis' blindness therapy Luxturna

Yahoo/Reuters

Spark Therapeutics

Flag link:

Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?

Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?

Endpoints

Spark Therapeutics

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Yahoo/Benzinga

Leap Therapeutics

Cidara Therapeutics

Spark Therapeutics

clinical trials

Flag link:

Roche, Spark push back takeover deadline in $4.3 billion deal

Roche, Spark push back takeover deadline in $4.3 billion deal

Yahoo/Reuters

Spark Therapeutics

Flag link:

Sangamo backs up early success for hemophilia gene therapy

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Spark Therapeutics

Flag link:

The top 10 most-expensive meds in the U.S.—and they're not the usual suspects

The top 10 most-expensive meds in the U.S.—and they're not the usual suspects

Fierce Pharma

Spark Therapeutics

Flag link:

FTC demands could mean months-long delay for Roche-Spark deal

FTC demands could mean months-long delay for Roche-Spark deal

Biopharma Dive

Spark Therapeutics

Flag link:

Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

Endpoints

Spark Therapeutics

Flag link:

What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay

What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay

Endpoints

Spark Therapeutics

Flag link:

Roche delays $4.3B Spark buyout — again — as FTC review drags on

Roche delays $4.3B Spark buyout — again — as FTC review drags on

Endpoints

Spark Therapeutics

Flag link:

Roche must ask Spark shareholders once again to sell

Roche must ask Spark shareholders once again to sell

Biopharma Dive

Spark Therapeutics

Flag link:

Gene therapy progress spurs competition in biotech buyouts

Gene therapy progress spurs competition in biotech buyouts

Biopharma Dive

Nightstar Therapeutics

Spark Therapeutics

Flag link:

Spark bidding war drove Roche bid up by $2.1 billion

Spark bidding war drove Roche bid up by $2.1 billion

BioCentury

Spark Therapeutics

Flag link:

Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy

Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy

Xconomy

Spark Therapeutics

Flag link:

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

Investors Business Daily

Spark Therapeutics

Flag link:

Uniqure turns the screw on Spark and Pfizer

Uniqure turns the screw on Spark and Pfizer

EP Vantage

Spark Therapeutics

Flag link:

Pages